0.3338
price up icon0.24%   0.0008
after-market アフターアワーズ: .32 -0.0138 -4.13%
loading
前日終値:
$0.333
開ける:
$0.3052
24時間の取引高:
4.03M
Relative Volume:
0.95
時価総額:
$9.29M
収益:
-
当期純損益:
$-22.71M
株価収益率:
-0.0285
EPS:
-11.71
ネットキャッシュフロー:
$-18.24M
1週間 パフォーマンス:
+21.38%
1か月 パフォーマンス:
+19.21%
6か月 パフォーマンス:
-69.38%
1年 パフォーマンス:
-86.21%
1日の値動き範囲:
Value
$0.291
$0.36
1週間の範囲:
Value
$0.2668
$0.374
52週間の値動き範囲:
Value
$0.215
$4.0899

Genprex Inc Stock (GNPX) Company Profile

Name
名前
Genprex Inc
Name
セクター
Healthcare (1170)
Name
電話
512-537-7997
Name
住所
1601 TRINITY STREET, BLDG. B, AUSTIN, TX
Name
職員
15
Name
Twitter
@genprex
Name
次回の収益日
2024-11-12
Name
最新のSEC提出書
Name
GNPX's Discussions on Twitter

GNPX を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
GNPX
Genprex Inc
0.3338 7.65M 0 -22.71M -18.24M -11.71
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.58 26.10B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
442.05 111.96B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.35 42.96M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
81.20 6.39B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
490.28 63.52B 14.09B 4.50B 2.96B 39.28

Genprex Inc Stock (GNPX) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2021-01-26 開始されました National Securities Buy
2019-04-29 開始されました Noble Capital Markets Outperform

Genprex Inc (GNPX) 最新ニュース

pulisher
May 29, 2025

Genprex to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting | GNPX Stock News - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Genprex to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting - PR Newswire

May 29, 2025
pulisher
May 28, 2025

Genprex Collaborators Present Positive Preclinical Data on Diabe - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Genprex (GNPX) Reports Promising Preclinical Data for Diabetes Gene Therapy | GNPX Stock News - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting - StreetInsider

May 28, 2025
pulisher
May 24, 2025

What Can Genprex Inc (NASDAQ: GNPX) Expect In 2025? - Stocksregister

May 24, 2025
pulisher
May 14, 2025

WestPark Capital Leads Placement for GNPX | GNPX Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Genprex (GNPX) to Release Quarterly Earnings on Wednesday - Defense World

May 14, 2025
pulisher
May 10, 2025

Things To Consider Before Buying Genprex Inc (NASDAQ: GNPX) - Stocksregister

May 10, 2025
pulisher
May 08, 2025

Genprex and University of Pittsburgh sign new agreement to study GPX-002 for diabetes - BioWorld MedTech

May 08, 2025
pulisher
May 07, 2025

Attention Investors: What’s Really Going On With Genprex Inc (NASDAQ: GNPX) - Stocksregister

May 07, 2025
pulisher
May 07, 2025

Genprex Announces Research Agreement for Diabetes Therapy - TipRanks

May 07, 2025
pulisher
May 07, 2025

Genprex (GNPX) Advances Diabetes Therapy Research with New Agreement | GNPX Stock News - GuruFocus

May 07, 2025
pulisher
May 07, 2025

Genprex Signs Sponsored Research Agreement with the University of Pittsburgh to Study Diabetes Gene Therapy in Type 1 and Type 2 Diabetes | GNPX Stock News - GuruFocus

May 07, 2025
pulisher
May 07, 2025

Genprex Signs Sponsored Research Agreement with the University of Pittsburgh to Study Diabetes Gene Therapy in Type 1 and Type 2 Diabetes - PR Newswire

May 07, 2025
pulisher
May 06, 2025

Genprex (GNPX) Secures Exclusive Patent License for Gene Therapy - GuruFocus

May 06, 2025
pulisher
May 06, 2025

Genprex (GNPX) Secures Exclusive Patent License for Gene Therapy | GNPX Stock News - GuruFocus

May 06, 2025
pulisher
May 06, 2025

Genprex Secures Exclusive Patent License for Reqorsa - TipRanks

May 06, 2025
pulisher
May 06, 2025

Genprex Signs Exclusive License to Additional Gene Therapy Techn - GuruFocus

May 06, 2025
pulisher
May 06, 2025

Genprex Signs Exclusive License to Additional Gene Therapy Technology with UTHealth Houston for the Treatment of Glioblastoma | GNPX Stock News - GuruFocus

May 06, 2025
pulisher
May 06, 2025

Genprex Signs Exclusive License to Additional Gene Therapy Technology with UTHealth Houston for the Treatment of Glioblastoma - PR Newswire

May 06, 2025
pulisher
May 05, 2025

Geode Capital Management LLC Grows Position in Genprex, Inc. (NASDAQ:GNPX) - Defense World

May 05, 2025
pulisher
May 02, 2025

Genprex Collaborators Selected to Present Positive Preclinical Data on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions - ADVFN

May 02, 2025
pulisher
May 02, 2025

Genprex collaborators report positive preclinical data on the use of Reqorsa gene therapy at the 2025 AACR Annual Meeting - SelectScience

May 02, 2025
pulisher
Apr 30, 2025

Genprex Inc (NASDAQ: GNPX) Is The Number One Stock Currently Moving. - Stocksregister

Apr 30, 2025
pulisher
Apr 30, 2025

Genprex (GNPX) Showcases Promising Results for Reqorsa Gene Ther - GuruFocus

Apr 30, 2025
pulisher
Apr 30, 2025

Genprex Collaborators Report Positive Preclinical Data On The Use Of Reqorsa Gene Therapy - TradingView

Apr 30, 2025
pulisher
Apr 30, 2025

Genprex Collaborators Report Positive Preclinical Data on the Us - GuruFocus

Apr 30, 2025
pulisher
Apr 30, 2025

Financial Metrics Check: Genprex Inc (GNPX)’s Ratios for Trailing Twelve Months - DWinneX

Apr 30, 2025
pulisher
Apr 30, 2025

Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Ras Inhibitor Resistant Lung Cancer at the 2025 AACR Annual Meeting - PR Newswire

Apr 30, 2025
pulisher
Apr 29, 2025

Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting - The Malaysian Reserve

Apr 29, 2025
pulisher
Apr 29, 2025

Genprex Collaborators to Present Positive Preclinical Data on Di - GuruFocus

Apr 29, 2025
pulisher
Apr 29, 2025

Taking the lead: Genprex Inc (GNPX) - Sete News

Apr 29, 2025
pulisher
Apr 29, 2025

Understanding the Risks of Investing in Genprex Inc (GNPX) - knoxdaily.com

Apr 29, 2025
pulisher
Apr 29, 2025

Genprex (GNPX) Secures Exclusive Patent License for Mesothelioma - GuruFocus

Apr 29, 2025
pulisher
Apr 28, 2025

Indo-Asian News Service - Indo-Asian News Service (IANS)

Apr 28, 2025
pulisher
Apr 28, 2025

Genprex secures exclusive license for mesothelioma gene therapy By Investing.com - Investing.com South Africa

Apr 28, 2025
pulisher
Apr 28, 2025

Genprex secures exclusive license for mesothelioma gene therapy - Investing.com Australia

Apr 28, 2025
pulisher
Apr 28, 2025

Choosing between riding the trend or protecting profits: Genprex Inc (GNPX) - uspostnews.com

Apr 28, 2025
pulisher
Apr 28, 2025

Genprex Inc (NASDAQ: GNPX) Stock’s Potential for Success in the Coming Months - Marketing Sentinel

Apr 28, 2025
pulisher
Apr 28, 2025

Genprex Signs Exclusive Technology License Agreement with New Yo - GuruFocus

Apr 28, 2025
pulisher
Apr 28, 2025

Genprex (GNPX) Secures Exclusive License for Gene Therapy Patent - GuruFocus

Apr 28, 2025
pulisher
Apr 28, 2025

Genprex Signs Agreement With New York University Langone Health - marketscreener.com

Apr 28, 2025
pulisher
Apr 28, 2025

Revolutionary Gene Therapy Shows 84% Target Success in Mesothelioma Treatment: Genprex-NYU Partnership - Stock Titan

Apr 28, 2025
pulisher
Apr 28, 2025

Genprex Signs Exclusive Technology License Agreement with New York University Langone Health for the Treatment of Mesothelioma - The Malaysian Reserve

Apr 28, 2025
pulisher
Apr 27, 2025

Short Interest in Genprex, Inc. (NASDAQ:GNPX) Grows By 487.6% - Defense World

Apr 27, 2025
pulisher
Apr 26, 2025

Stock Market Recap: Genprex Inc (GNPX) Concludes at 0.27, a 0.57 Surge/Decline - DWinneX

Apr 26, 2025
pulisher
Apr 24, 2025

GNPXGenprex Inc Latest Stock News & Market Updates - Stock Titan

Apr 24, 2025
pulisher
Apr 24, 2025

GNPX’s Stock Market Puzzle: Piecing Together 2023’s Performance - investchronicle.com

Apr 24, 2025
pulisher
Apr 24, 2025

Now Is The Time To Build A Position In Genprex Inc (NASDAQ:GNPX) - Marketing Sentinel

Apr 24, 2025
pulisher
Apr 24, 2025

Genprex Selected to Present Trial Design of Acclaim-3 Clinical T - GuruFocus

Apr 24, 2025

Genprex Inc (GNPX) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$1.08
price up icon 1.89%
$30.14
price down icon 3.74%
$573.26
price down icon 1.32%
$304.56
price up icon 3.98%
$4.50
price down icon 3.02%
$490.28
price down icon 19.01%
大文字化:     |  ボリューム (24 時間):